%0 Journal Article
%T Clinical use of biomarkers in the field of cytotoxic nucleoside analogues.
%A Jordheim LP
%J Nucleosides Nucleotides Nucleic Acids
%V 0
%N 0
%D 2023 Oct 24
%M 37874211
%F 1.449
%R 10.1080/15257770.2023.2272640
%X <B>UNASSIGNED: </B>Cytotoxic nucleosides (gemcitabine, cytarabine…) are used for the treatment of various malignancies. Their activity is dependent on the interaction with several proteins and enzymes of nucleotide metabolism. It has for a long time been hypothesized that the clinical activity of nucleoside analogues can be predicted by studying corresponding genes or gene products in clinical samples.<BR><B>UNASSIGNED: </B>In this short review, I will present old and new published data from our group and others about the prediction of activity of these drugs concentrating on gene-candidate approaches, and discuss biological and technical limitations of these.<BR><B>UNASSIGNED: </B>A large number of studies have been conducted in various clinical settings (drugs, disease, patient cohort…) evaluating DNA, mRNA or protein-related markers. Although some individual parameters and associations thereof have been validated, only a very few numbers have been implemented in pretreatment evaluations of patients.<BR><B>UNASSIGNED: </B>There is still much to do in the field of outcome-prediction with nucleoside analogues. The use of multiparametric methods could increase the success rate but at the cost of a poorer understanding of molecular mechanisms.